(S1 (S (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NN spironolactone))) (PP (IN on) (NP (NP (NN corneal) (NN allograft) (NN survival)) (PP (IN in) (NP (DT the) (NN rat))))))) (. .)))
(S1 (S (NP (NP (NN PURPOSE)) (: :) (S (NP (NN Spironolactone)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB have) (NP (JJ suppressive) (NNS effects)) (PP (IN on) (NP (JJ several) (ADJP (ADJP (JJ immunoactive)) (CC and) (ADJP (JJ proinflammatory))) (NNS cytokines)))))))))) (. .))))
(S1 (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN spironolactone))) (PP (IN on) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NN corneal) (NN allograft) (NN rejection))) (PP (IN in) (NP (DT a) (NN MHC) (NN class) (NN I/II) (NN mismatch) (NN rat) (NN corneal) (NN transplant) (NN model))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (JJ Grafted) (NNS animals)) (PP (IN for) (NP (NN corneal) (NN survival) (NN analysis)))) (VP (VBD were) (VP (VBN assigned) (S (VP (TO to) (VP (VP (VBP receive) (NP (CC either) (NP (NP (NN spironolactone) (NN suspension)) (PRN (-LRB- -LRB-) (NP (ADVP (RB orally)) (, ,) (NP (CD 100) (NN mg/kg/day))) (, ,) (S (NP (NN n)) (VP (JJ =) (NP (CD 7)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ phosphate-buffered) (NN saline)) (PRN (-LRB- -LRB-) (NP (NP (NN PBS)) (, ,) (ADVP (RB orally)) (, ,) (NP (NP (JJ same) (NN volume)) (PP (IN as) (NP (NP (NN spironolactone)) (, ,) (NP (NP (NN n)) (ADJP (JJ =) (NP (CD 9)))))))) (-RRB- -RRB-))))) (CC or) (VP (VBD remained) (ADJP (JJ untreated)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 16)) (-RRB- -RRB-))))))))) (. .))))
(S1 (S (S (NP (NP (JJ Additional) (JJ grafted) (NNS rats)) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NN spironolactone)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 6)) (-RRB- -RRB-))) (CC or) (NP (NP (NNS PBS)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 8)) (-RRB- -RRB-))))))) (VP (VBD were) (VP (VBN sacrificed) (PP (IN on) (NP (NN day) (CD 12))) (PP (IN for) (NP (NP (JJ quantitative) (NN RT-PCR) (NN analysis)) (PP (IN for) (NP (JJ mechanistic) (NNS studies)))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN Mean) (-LRB- -LRB-) (NN +/-SEM) (-RRB- -RRB-) (NN graft) (NN survival)) (VP (VBD was) (ADJP (RB significantly) (JJ prolonged)) (PP (IN in) (NP (NP (NNS animals)) (VP (VBG receiving) (NP (NP (NN spironolactone)) (PRN (-LRB- -LRB-) (NP (QP (CD 14.9) (CC +/-) (CD 2.0)) (NNS days)) (-RRB- -RRB-)))))) (PP (VBN compared) (PP (IN with) (NP (NP (ADJP (CC both) (ADJP (ADJP (JJ PBS-treated)) (PRN (-LRB- -LRB-) (NP (QP (CD 12.3) (CC +/-) (CD 1.2)) (NNS days)) (, ,) (NP (NN p) (JJ =) (NN 0.007)) (-RRB- -RRB-))) (CC and) (ADJP (JJ untreated))) (NNS controls)) (PRN (-LRB- -LRB-) (NP (QP (CD 13.0) (CC +/-) (CD 1.0)) (NNS days)) (, ,) (NP (NN p) (JJ =) (CD 0.01)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NN corneal) (NN neovascularization)) (PP (IN in) (NP (JJ spironolactone-treated) (NNS rats)))))) (PP (VBN compared) (PP (IN with) (NP (DT the) (JJ PBS-treated) (NN group)))) (, ,) (SBAR (IN although) (S (NP (DT the) (NN difference)) (VP (VBD was) (RB not) (ADJP (RB statistically) (JJ significant))))))) (. .)))
(S1 (S (S (NP (NN Spironolactone)) (VP (VBD affected) (NP (ADJP (CC both) (ADJP (JJ systemic) (PRN (-LRB- -LRB-) (NP (NP (NN down-regulation)) (PP (IN of) (NP (NP (JJ CD25+) (NNS cells)) (PP (IN in) (NP (NN spleen)))))) (-RRB- -RRB-))) (CC and) (ADJP (JJ local))) (JJ immune) (NN response)) (-LRB- -LRB-) (NP (NP (NN up-regulation)) (PP (IN of) (NP (NN IL-10))) (PP (IN in) (NP (NN cornea)))) (-RRB- -RRB-))) (. .)))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (PRP We)) (VP (VBP present) (NP (NP (JJ initial) (NNS results)) (VP (VBG demonstrating) (NP (NP (JJ anti-inflammatory) (NNS effects)) (PP (IN of) (NP (NN spironolactone)))))))) (. .))))
